Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tripartite motif containing 40 (TRIM40) is a member of the TRIM protein family acting as an E3 ubiquitin-protein ligase with important roles as a negative regulator of inflammation and carcinogenesis, particularly in the gastrointestinal tract[1][2][5]. It limits the innate immune response by ubiquitinating and targeting receptors in the RLR (RIG-I-like receptor) pathway for degradation, thus dampening antiviral signaling[2][5]. It also promotes the neddylation of IKBKG/NEMO, contributing to stabilization of NFKBIA and inhibition of NF-kappa-B translocation and activity[1][5]. Research indicates TRIM40 interacts with ROCK1 and can inhibit cancer cell proliferation via the c-Myc/p21 axis, and its dysregulation may be implicated in gastrointestinal cancers and chronic inflammation[4]. No known therapeutics or biomarkers are currently associated with this target, and no main safety concerns are reported in the available literature[1][5].
Targeted protein ubiquitination for proteasomal degradation Promotion of neddylation and stabilization of specific immune components
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tripartite motif containing 40 (TRIM40).